Patients with MAPT mutations are affected by the earlier initiation of PSP symptoms than carriers of less common genetic features such as leucine-rich repeat kinase 2 (LRRK2) or dynactin subunit 1 (DCTN1) [19]. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.